November 2019 Pharmaceutical Schedule Dispatch
This dispatch email is provided to pharmacists as an early notification of the changes to be announced in the November 2019 Update to the Pharmaceutical Schedule.

New listings
- Amoxicillin (Alphamox) cap 250 mg (p’code 2362716) and cap 500 mg (p’code 2362724) – up to 30 cap available on a PSO and up to 10 x the maximum PSO quantity for RFPP
- Benzylpenicillin sodium [penicillin G] (Pan-Penicillin G Sodium) inj 600 mg (1 million units) vial – up to 5 inj available on a PSO, S29 and wastage claimable (p’code 2577224)
- Buprenorphine with naloxone (Buprenorphine Naloxone BNM) tab sublingual 2 mg with naloxone 0.5 mg (p’code 2574004) and tab sublingual 8 mg with naloxone 2 mg (p’code 2574012) – Special Authority – Retail pharmacy, no patient no-payment payable and safety medicine; prescriber may determine dispensing frequency
- Compound electrolytes (Electral) powder for oral soln – up to 10 sach available on a PSO (P’code 2576937)
- Enteral feed 2kcal/ml (Nutrison Concentrated) liquid, 500 ml OP – Special Authority - Hospital pharmacy [HP3] (p’code 2572966)
- Extensively hydrolysed formula (Allerpro 1) powder, 900 g OP – Special Authority – Hospital pharmacy [HP3] (p’code 2577410)
- Extensively hydrolysed formula (Allerpro 2) powder, 900 g OP – Special Authority – Hospital pharmacy [HP3] (p’code 2577429)
- Fluoxetine hydrochloride (Fluox) tab dispersible 20 mg, scored – subsidy by endorsement (p’code 2077817)
- Fluoxetine hydrochloride (Fluox) cap 20 mg (p’code 2353121)
- Levomepromazine hydrochloride (Nozinan) inj 25 mg per ml, 1 ml ampoule – safety medicine; prescriber may determine dispensing frequency (p’code 549142)
- Levonorgestrel (Jaydess) intra-uterine device 13.5 mg (p’code 2474891)
- Measles, mumps and rubella (MMR II) inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml – restriction applies (p’code 2577372)
- Ondansetron (Onrex) tab 4 mg (p’code 2441306) and tab 8 mg (p’code 2441314)
- Paraffin (healthE) white soft, 450 g (p’code 2322099) and 2,500 g (p’code 2322080) – only in combination

Changes to restrictions, chemical names and presentations
- Adrenaline (DBL Adrenaline) inj 1 in 1,000, 1 ml ampoule – amended brand name
- Cefalexin (Cefalexin Sandoz) grans for oral liq 25 mg per ml and 50 mg per ml – note removed
- Clarithromycin tab 250 mg (Apo-Clarithromycin) and grans for oral liq 250 mg per 5 ml (Klacid) – amended Special Authority criteria
- Eptacog alfa [recombinant factor VIIA] (NovoSeven RT) inj 1 mg, 2 mg, 5 mg and 8 mg syringe – amended note
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 U, 1,000 U and 2,500 U – amended note
- Levonorgestrel (Mirena) intra-uterine device 52 mg – Special Authority removed and amended presentation description
- Measles, mumps and rubella vaccine (Priorix) inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml – Xpharm removed, amended restriction and sole supply suspended
- Moroctocog alfa [recombinant factor VIII] (Xyntha) inj 250 ui, 500 ui, 1,000 ui, 2,000 ui and 3,000 ui prefilled syringe – amended note
- Octocog alfa [recombinant factor VIII] (Advate) inj 250 ui, 500 ui, 1,000 ui, 1,500 ui, 2,000 ui and 3,000 vial – amended note
- Octocog alfa [recombinant factor VIII] (Kogenate FS) inj 250 ui, 500 ui, 1,000 ui, 2,000 ui and 3,000 vial – amended note
- Ranitidine tab 150 mg and 300 mg (Ranitidine Relief), oral liq 150 mg per 10 ml (Peptisoothe) and inj 25 mg per ml, 2 ml (Zantac) – addition of subsidy by endorsement
- Standard supplements – amended Special Authority criteria
- Tocilizumab inj 20 mg per ml, 4 ml vial, 10 ml vial and 20 ml vial (Actemra) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria

**Increased subsidy**

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amisulpride</td>
<td>Tab 400 mg</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Bacillus Calmette-guerin (BCG) vaccine</td>
<td>Inj 40 mg per ml, vial</td>
<td>SII-Onco-BCG</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>Tab 200 mg</td>
<td>Antabuse</td>
</tr>
<tr>
<td>Loratadine</td>
<td>tab 10 mg</td>
<td>Lorafix</td>
</tr>
<tr>
<td>Measles, mumps and rubella vaccine</td>
<td>Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml</td>
<td>Priorix</td>
</tr>
<tr>
<td>Moroctocog alfa [recombinant factor VIII]</td>
<td>Inj 250 ui, 500 ui, 1,000 ui, 2,000 ui and 3,000 ui prefilled syringe</td>
<td>Xyntha</td>
</tr>
</tbody>
</table>